JPH07508401A - 動物およびヒトにおける呼吸器合胞体ウイルス感染治療ならびに予防用新規抗体 - Google Patents

動物およびヒトにおける呼吸器合胞体ウイルス感染治療ならびに予防用新規抗体

Info

Publication number
JPH07508401A
JPH07508401A JP5517272A JP51727293A JPH07508401A JP H07508401 A JPH07508401 A JP H07508401A JP 5517272 A JP5517272 A JP 5517272A JP 51727293 A JP51727293 A JP 51727293A JP H07508401 A JPH07508401 A JP H07508401A
Authority
JP
Japan
Prior art keywords
antibody
sequence
seq
chain
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP5517272A
Other languages
English (en)
Japanese (ja)
Inventor
テイラー,ジェラルディン
ストット,エドワード・ジェームズ
Original Assignee
スコットジェン・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スコットジェン・リミテッド filed Critical スコットジェン・リミテッド
Publication of JPH07508401A publication Critical patent/JPH07508401A/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027Paramyxoviridae, e.g. respiratory syncytial virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/18011Paramyxoviridae
    • C12N2760/18511Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP5517272A 1992-04-06 1993-04-06 動物およびヒトにおける呼吸器合胞体ウイルス感染治療ならびに予防用新規抗体 Pending JPH07508401A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929207479A GB9207479D0 (en) 1992-04-06 1992-04-06 Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man
GB9207479.8 1992-04-06
PCT/GB1993/000725 WO1993020210A1 (en) 1992-04-06 1993-04-06 Antibodies for treatment and prevention of respiratory syncytial virus infection

Publications (1)

Publication Number Publication Date
JPH07508401A true JPH07508401A (ja) 1995-09-21

Family

ID=10713521

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5517272A Pending JPH07508401A (ja) 1992-04-06 1993-04-06 動物およびヒトにおける呼吸器合胞体ウイルス感染治療ならびに予防用新規抗体

Country Status (9)

Country Link
EP (1) EP0636182A1 (ko)
JP (1) JPH07508401A (ko)
KR (1) KR950701386A (ko)
AU (1) AU679440B2 (ko)
CA (1) CA2133662A1 (ko)
GB (1) GB9207479D0 (ko)
NZ (1) NZ251405A (ko)
WO (1) WO1993020210A1 (ko)
ZA (1) ZA932445B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015509091A (ja) * 2012-01-09 2015-03-26 ザ スクリプス リサーチ インスティテュート ヒト化抗体

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US6258529B1 (en) * 1994-12-01 2001-07-10 Oravax, Inc. PCR amplification of rearranged genomic variable regions of immunoglobulin genes
US7175847B1 (en) 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US7153508B2 (en) 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
WO1997010846A1 (en) 1995-09-18 1997-03-27 Intracel Corporation Neutralizing monoclonal antibodies to respiratory syncytial virus
FR2758331B1 (fr) * 1997-01-14 1999-03-05 Univ Bourgogne Nouveaux moyens pour le diagnostic, la prevention et le traitement vis-a-vis de contaminations ou d'infections par des virus a tropisme muqueux
US6160099A (en) * 1998-11-24 2000-12-12 Jonak; Zdenka Ludmila Anti-human αv β3 and αv β5 antibodies
EP1278545A1 (en) * 2000-05-03 2003-01-29 Medimmune, Inc. Combination therapy of respiratory diseases using antibodies
AU2001263443A1 (en) * 2000-05-25 2001-12-03 Med Immune, Inc. F-protein epitope-based vaccine for respiratory syncytial virus infection
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
TW200636064A (en) * 2004-10-28 2006-10-16 Centocor Inc Anti-respiratory syncytial virus antibodies, antigens and uses thereof
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
RU2551963C2 (ru) 2010-09-09 2015-06-10 Пфайзер Инк. Молекулы, связывающиеся с 4-1вв
FR2970968A1 (fr) * 2011-02-01 2012-08-03 Isp Investments Inc Nouveaux peptides intervenant dans la voie de signalisation scf c-kit et compositions les comprenant
US9364414B2 (en) 2011-02-01 2016-06-14 Isp Investments Inc. Method to protect skin from ultraviolet radiation using novel peptides involved in the improvement of microparasol organization in keratinocytes
CA2863224A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
CN105073781A (zh) 2013-01-11 2015-11-18 加州生物医学研究所 牛融合抗体
EP3022221B1 (en) * 2013-07-18 2021-09-15 Taurus Biosciences, LLC Humanized antibodies with ultralong complementarity determining regions
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
US20210347862A1 (en) * 2018-09-03 2021-11-11 Pontificia Universidad Catolica De Chile Specific monoclonal antibody against the n antigen of human respiratory syncytial virus (hrsv) useful for treating infection, detection thereof and diagnosis
EP4265637A1 (en) * 2020-12-18 2023-10-25 Zhuhai Trinomab Pharmaceutical Co., Ltd. Respiratory syncytial virus-specific binding molecule

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989005823A1 (en) * 1987-12-23 1989-06-29 The Upjohn Company Chimeric glycoproteins containing immunogenic segments of the glycoproteins of human respiratory syncytial virus
CA2087100A1 (en) * 1990-07-19 1992-01-20 Robert M. Chanock Immunotherapeutic method of preventing or treating viral respiratory tract disease
GB9019812D0 (en) * 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
ATE231002T1 (de) * 1992-09-16 2003-02-15 Scripps Research Inst Menschliche, neutralisierende, monoklonale antikörper gegen das respiratorische synzytialvirus
WO1994017105A1 (en) * 1993-01-29 1994-08-04 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015509091A (ja) * 2012-01-09 2015-03-26 ザ スクリプス リサーチ インスティテュート ヒト化抗体
JP2020036611A (ja) * 2012-01-09 2020-03-12 ザ スクリプス リサーチ インスティテュート ヒト化抗体

Also Published As

Publication number Publication date
AU3900093A (en) 1993-11-08
GB9207479D0 (en) 1992-05-20
NZ251405A (en) 1997-09-22
ZA932445B (en) 1995-01-05
EP0636182A1 (en) 1995-02-01
WO1993020210A1 (en) 1993-10-14
CA2133662A1 (en) 1993-10-14
KR950701386A (ko) 1995-03-23
AU679440B2 (en) 1997-07-03

Similar Documents

Publication Publication Date Title
JPH07508401A (ja) 動物およびヒトにおける呼吸器合胞体ウイルス感染治療ならびに予防用新規抗体
JP5642972B2 (ja) C型肝炎ウイルス(hcv)に対するヒト抗体およびその使用
AU654827B2 (en) Novel antibodies for treatment and prevention of infection in animals and man
KR101671452B1 (ko) 항rsv g 단백질 항체
AU2011219488B2 (en) Antagonist anti-IL-7 receptor antibodies and methods
CN102143975B (zh) 特异性配体在msrv相关疾病中的治疗用途
JP2011019516A (ja) クロストリジウム・ディフィシル(Clostridiumdifficile)毒素に対する抗体およびその使用
TW201522367A (zh) 結合到rsv g蛋白之人類抗體
TW201534619A (zh) 結合到rsv g蛋白之人類抗體
WO1993020210A9 (en) Antibodies for treatment and prevention of respiratory syncytial virus infection
US20230065377A1 (en) Human antibodies to alphaviruses
JP2001510329A (ja) ヒトモノクローナル抗体
US20220235117A1 (en) Novel anti-hepatitis b virus antibody and uses thereof
US20240101645A1 (en) Monoclonal antibodies against coronaviruses and uses thereof
CN114751988A (zh) 中和冠状病毒的多特异性抗体
CN114751987A (zh) 一种中和冠状病毒的多特异性抗体
CN114751986A (zh) 中和新冠病毒的多特异性抗体
AU2013251185A1 (en) Human antibodies against hepatitis C virus (HCV) and uses thereof
NZ250415A (en) Monoclonal antibody directed against rsv epitope 417-438, its use and production